New Zealand markets open in 2 hours 36 minutes

MiNK Therapeutics, Inc. (INKT)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.9600-0.0300 (-3.03%)
At close: 04:00PM EDT
0.9502 -0.01 (-1.02%)
After hours: 06:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9900
Open0.9900
Bid0.9294 x 100
Ask0.9998 x 100
Day's range0.9501 - 1.0200
52-week range0.7500 - 3.3400
Volume44,736
Avg. volume188,825
Market cap37.793M
Beta (5Y monthly)0.03
PE ratio (TTM)N/A
EPS (TTM)-0.6500
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
  • GlobeNewswire

    MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

    NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These

  • GuruFocus.com

    MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...

    Discover how MiNK Therapeutics Inc navigates financial challenges and advances key clinical programs amidst strategic operational adjustments.

  • GlobeNewswire

    MiNK Reports First Quarter 2024 Results

    Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, in